BEAMing

The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.

Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.

The firms will set up sites for OncoBEAM RAS CRC in Argentina, Brazil, Malaysia, Indonesia, Vietnam, and India, and present data at major medical conferences.

The firms now plan to market the test in Europe, Asia, and Australia as a tool oncologists can use to identify best responders to EGFR inhibitors.

The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.

As part of the CORRECT trial, researchers compared analyses of liquid and tissue biopsies, finding support for using circulating DNA to follow tumor progression.

Vall d'Hebron's Institute of Oncology will use the liquid biopsy-based OncoBEAM RAS test to research precision medicine approaches for metastatic colorectal cancer patients.

Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.

NEW YORK (GenomeWeb) — In a deal signed ceremoniously at the American Society of Clinical Oncology meeting earlier this week in Chicago, Merck and Sysmex Inostics will collaborate to develop and commercialize a kit to assay RAS mutations in circulating tumor DNA.

NEW YORK (GenomeWeb News) — Roche said today that it has licensed its emulsion PCR patent portfolio to Sysmex Inostics.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.